Invion Limited (IVX.XA)
Cboe AU · AUD
A$0.036 (+0.00%) as of
Key statistics
- EPS (TTM)
- -0.0000
- 52-week range
- 0.0330 – 0.1100
- Beta
- 0.45
- Revenue (TTM)
- 384.71k
- Profit margin
- 0.00%
- Volume
- 108.44k
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.